Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke

医学 特奈特普酶 溶栓 改良兰金量表 闭塞 冲程(发动机) 随机对照试验 纤溶剂 内科学 麻醉 组织纤溶酶原激活剂 缺血 缺血性中风 心肌梗塞 机械工程 工程类
作者
Bruce Campbell,Peter Mitchell,Leonid Churilov,Nawaf Yassi,Timothy Kleinig,Richard Dowling,Bernard Yan,Steven Bush,Vincent Thijs,Rebecca Scroop,Marion Simpson,Mark Brooks,Hamed Asadi,Teddy Y. Wu,Darshan Shah,Tissa Wijeratne,Henry Zhao,Fana Alemseged,Felix Ng,Peter Bailey
出处
期刊:JAMA [American Medical Association]
卷期号:323 (13): 1257-1257 被引量:227
标识
DOI:10.1001/jama.2020.1511
摘要

Importance

Intravenous thrombolysis with tenecteplase improves reperfusion prior to endovascular thrombectomy for ischemic stroke compared with alteplase.

Objective

To determine whether 0.40 mg/kg of tenecteplase safely improves reperfusion before endovascular thrombectomy vs 0.25 mg/kg of tenecteplase in patients with large vessel occlusion ischemic stroke.

Design, Setting, and Participants

Randomized clinical trial at 27 hospitals in Australia and 1 in New Zealand using open-label treatment and blinded assessment of radiological and clinical outcomes. Patients were enrolled from December 2017 to July 2019 with follow-up until October 2019. Adult patients (N = 300) with ischemic stroke due to occlusion of the intracranial internal carotid, \basilar, or middle cerebral artery were included less than 4.5 hours after symptom onset using standard intravenous thrombolysis eligibility criteria.

Interventions

Open-label tenecteplase at 0.40 mg/kg (maximum, 40 mg; n = 150) or 0.25 mg/kg (maximum, 25 mg; n = 150) given as a bolus before endovascular thrombectomy.

Main Outcomes and Measures

The primary outcome was reperfusion of greater than 50% of the involved ischemic territory prior to thrombectomy, assessed by consensus of 2 blinded neuroradiologists. Prespecified secondary outcomes were level of disability at day 90 (modified Rankin Scale [mRS] score; range, 0-6); mRS score of 0 to 1 (freedom from disability) or no change from baseline at 90 days; mRS score of 0 to 2 (functional independence) or no change from baseline at 90 days; substantial neurological improvement at 3 days; symptomatic intracranial hemorrhage within 36 hours; and all-cause death.

Results

All 300 patients who were randomized (mean age, 72.7 years; 141 [47%] women) completed the trial. The number of participants with greater than 50% reperfusion of the previously occluded vascular territory was 29 of 150 (19.3%) in the 0.40 mg/kg group vs 29 of 150 (19.3%) in the 0.25 mg/kg group (unadjusted risk difference, 0.0% [95% CI, −8.9% to −8.9%]; adjusted risk ratio, 1.03 [95% CI, 0.66-1.61];P = .89). Among the 6 secondary outcomes, there were no significant differences in any of the 4 functional outcomes between the 0.40 mg/kg and 0.25 mg/kg groups nor in all-cause deaths (26 [17%] vs 22 [15%]; unadjusted risk difference, 2.7% [95% CI, −5.6% to 11.0%]) or symptomatic intracranial hemorrhage (7 [4.7%] vs 2 [1.3%]; unadjusted risk difference, 3.3% [95% CI, −0.5% to 7.2%]).

Conclusions and Relevance

Among patients with large vessel occlusion ischemic stroke, a dose of 0.40 mg/kg, compared with 0.25 mg/kg, of tenecteplase did not significantly improve cerebral reperfusion prior to endovascular thrombectomy. The findings suggest that the 0.40-mg/kg dose of tenecteplase does not confer an advantage over the 0.25-mg/kg dose in patients with large vessel occlusion ischemic stroke in whom endovascular thrombectomy is planned.

Trial Registration

ClinicalTrials.gov Identifier:NCT03340493
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
虚心蜗牛完成签到 ,获得积分10
1秒前
3秒前
量子星尘发布了新的文献求助10
3秒前
nightmare完成签到,获得积分20
4秒前
哭泣笑柳发布了新的文献求助10
5秒前
nightmare发布了新的文献求助10
7秒前
大橙子发布了新的文献求助10
10秒前
12秒前
Zhh完成签到 ,获得积分10
12秒前
Tina完成签到,获得积分10
14秒前
微生完成签到 ,获得积分10
14秒前
15秒前
chhzz完成签到 ,获得积分10
16秒前
飞舞伤寒发布了新的文献求助20
16秒前
曾珍发布了新的文献求助10
18秒前
qwe完成签到,获得积分10
19秒前
Xdz完成签到 ,获得积分10
19秒前
cai完成签到 ,获得积分10
22秒前
雨恋凡尘完成签到,获得积分0
25秒前
羊羔肉完成签到,获得积分10
27秒前
胖丁完成签到,获得积分10
27秒前
笨笨凡松完成签到,获得积分10
30秒前
飞舞伤寒完成签到,获得积分10
30秒前
贝利亚完成签到,获得积分10
32秒前
喜多多的小眼静完成签到 ,获得积分10
32秒前
32秒前
Dsunflower完成签到 ,获得积分10
33秒前
羊羔肉发布了新的文献求助50
34秒前
半夏发布了新的文献求助10
34秒前
35秒前
35秒前
大橙子发布了新的文献求助10
36秒前
星辰大海应助贝利亚采纳,获得10
36秒前
37秒前
sunny心晴完成签到 ,获得积分10
39秒前
独特的凝云完成签到 ,获得积分10
39秒前
TheDing完成签到,获得积分10
40秒前
传奇3应助lenetivy采纳,获得10
42秒前
积极的忆曼完成签到,获得积分10
43秒前
量子星尘发布了新的文献求助10
43秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038201
求助须知:如何正确求助?哪些是违规求助? 3575940
关于积分的说明 11373987
捐赠科研通 3305747
什么是DOI,文献DOI怎么找? 1819274
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022